Search Result

Results for "

VEGFR3 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (17) Aurora Kinase (3) Autophagy (20) c-Fms (5) c-Kit (13) c-Met/HGFR (1) Discoidin Domain Receptor (2) ERK (1) FAK (2) Ferroptosis (7) FGFR (14) FLT3 (14) Histamine Receptor (2) Isotope-Labeled Compounds (4) PDGFR (19) Raf (7) Src (2) Trk Receptor (2) VEGFR (51)
By Research Areas:	Cancer (51) Cardiovascular Disease (2) Endocrinology (2) Inflammation/Immunology (2) Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15458A

(S)-SAR131675	VEGFR	Cancer
(S)-SAR131675 is the S-enantiomer of SAR131675 (HY-15458), a potent and selective *VEGFR3* inhibitor and a click chemistry reagent .

HY-19986

AAL993	VEGFR	Cardiovascular Disease Cancer
IC₅₀s of 130 nM, 23 nM, and 18 nM for VEGFR1, VEGFR2, and VEGFR3, respectively. AAL993 shows less potently inhibits other tyrosine kinases. AAL993 possesses potent antiangiogenic and antitumor properties .

HY-132305

VEGFR-3-IN-1	VEGFR	Cancer
VEGFR-3-IN-1 is a potent and selective *VEGFR3* inhibitor with an IC₅₀ of 110.4 nM. VEGFR-3-IN-1 significantly inhibits proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231, and MDA-MB-436 cells by inactivating the VEGFR3 signaling pathway, and also effectively inhibits breast cancer growth .

HY-B1305

Chloropyramine hydrochloride	FAK Histamine Receptor VEGFR	Endocrinology Cancer
Chloropyramine hydrochloride is a histamine receptor H1 antagonist which can also inhibit the biochemical function of *VEGFR-3* and FAK.

HY-116624

MAZ51 3 Publications Verification	VEGFR Apoptosis	Cancer
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ. MAZ51 blocks proliferation and induces apoptosis in a wide variety of tumor cells. Antitumor activity .

HY-12060

KRN-633 3 Publications Verification	VEGFR	Cancer
KRN-633 is a potent *VEGFR* inhibitor with IC₅₀s of 170, 160 and 125 nM for VEGFR1, VEGFR2 and VEGFR3, respectively.

HY-145633

Sozinibercept OPT 302; VGX-300	VEGFR	Cardiovascular Disease
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of *VEGF-C/D, which are the proangiogenic factors, inhibiting* angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .

HY-123050

(Rac)-SAR131675	VEGFR	Neurological Disease
(Rac)-SAR131675 is the racemate of SAR131675. SAR131675 is a potent and selective *VEGFR3* inhibitor with an IC₅₀ of 23 nM .

HY-10201S1

Sorafenib-d4 Bay 43-9006-d₄	Raf VEGFR FLT3 Ferroptosis Autophagy Apoptosis	Cancer
Sorafenib-d₄ is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

HY-B1305R

Chloropyramine hydrochloride (Standard)	FAK Histamine Receptor VEGFR	Endocrinology Cancer
Chloropyramine hydrochloride (Standard) is the analytical standard of Chloropyramine hydrochloride. This product is intended for research and analytical applications. Chloropyramine hydrochloride is a histamine receptor H1 antagonist which can also inhibit the biochemical function of VEGFR-3 and FAK.

HY-10201S

Sorafenib-d3 Donafenib; Bay 43-9006-d₃	Raf VEGFR FLT3 Ferroptosis Autophagy Apoptosis	Cancer
Sorafenib-d₃ (Donafenib), a deuterated compound of Sorafenib, is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC₅₀s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively .

HY-10527

Telatinib 1 Publications Verification Bay 57-9352	c-Kit PDGFR VEGFR	Cancer
Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of *VEGFR2, VEGFR3, PDGFα, and c-Kit* with IC₅₀s of 6, 4, 15 and 1 nM, respectively.

HY-10527C

Telatinib mesylate 1 Publications Verification Bay 57-9352 mesylate	VEGFR PDGFR c-Kit	Cancer
Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active *VEGFR2, VEGFR3, PDGFα, and c-Kit* inhibitor with IC₅₀s of 6 nM, 4 nM, 15 nM and 1 nM, respectively .

HY-19624

NVP-ACC789 ACC-789; ZK202650	VEGFR PDGFR	Cancer
NVP-ACC789 is an inhibitor of human *VEGFR-1, VEGFR-2* (mouse *VEGFR-2), VEGFR-3* and PDGFR-β with IC₅₀s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.

HY-10065

Axitinib 20+ Cited Publications AG-013736	VEGFR PDGFR	Cancer
Axitinib is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 0.1, 0.2, 0.1-0.3, 1.6 nM for *VEGFR1, VEGFR2, VEGFR3* and PDGFRβ, respectively.

HY-15458

SAR131675 5+ Cited Publications	VEGFR	Cancer
SAR131675 is a potent and selective *VEGFR3* inhibitor with an IC₅₀ of 23 nM. SAR131675 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-100019

Rogaratinib 5 Publications Verification BAY1163877	FGFR	Cancer
Rogaratinib (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. Rogaratinib inhibits FGFRs with IC50s of 11.2 nM (FGFR1), <1 nM (FGFR2), 18.5 nM (FGFR3), 127 nM (VEGFR3/FLT4), 201 nM (FGFR4), respectively .

HY-12009

Pazopanib Hydrochloride 15+ Cited Publications GW786034 Hydrochloride	PDGFR VEGFR FGFR c-Kit c-Fms Autophagy	Cancer
Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of *VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms* with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-15506

TAK-593 1 Publications Verification	PDGFR VEGFR	Cancer
TAK-593 is a potent *VEGFR* and PDGFR family inhibitor with IC₅₀s of 3.2, 0.95, 1.1, 4.3 and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα and PDFGRβ, respectively.

HY-10208

Pazopanib 15+ Cited Publications GW786034	VEGFR c-Kit PDGFR Autophagy FGFR	Cancer
Pazopanib (GW786034) is a novel multi-target inhibitor of *VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms* with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-120661

T-1840383	c-Met/HGFR VEGFR	Cancer
T-1840383 is a potent, ATP-competitive inhibitor of *c-Met/VEGFR-2, with the IC₅₀s of 1.9 nM, 7.7 nM, 2.2 nM and 5.5 nM for c-Met, VEGFR1, VEGFR2* and *VEGFR3*, respectively .

HY-10987A

ENMD-2076 3 Publications Verification	Aurora Kinase FLT3 VEGFR FGFR PDGFR Src Apoptosis	Cancer
ENMD-2076 is a multi-targeted kinase inhibitor with IC₅₀s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, *KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα*, respectively.

HY-15391

Lucitanib 5+ Cited Publications E-3810	VEGFR FGFR	Cancer
Lucitanib (E-3810) is a novel dual inhibitor of *VEGFR* and FGFR, potently and selectively inhibits *VEGFR1, VEGFR2, VEGFR3, FGFR1* and FGFR2 with IC₅₀s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively .

HY-15391A

Lucitanib dihydrochloride	VEGFR FGFR	Cancer
Lucitanib (E-3810) dihydrochloride is a novel dual inhibitor of *VEGFR* and FGFR, potently and selectively inhibits *VEGFR1, VEGFR2, VEGFR3, FGFR1* and FGFR2 with IC₅₀s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively .

HY-10260

Vandetanib 15+ Cited Publications ZD6474	VEGFR Autophagy Apoptosis	Cancer
Vandetanib (D6474) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

HY-10987

ENMD-2076 Tartrate 3 Publications Verification	Aurora Kinase FLT3 VEGFR FGFR Src PDGFR Apoptosis	Cancer
ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC₅₀s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, *KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα*, respectively.

HY-10260B

Vandetanib hydrochloride ZD6474 hydrochloride	VEGFR Autophagy Apoptosis	Cancer
Vandetanib hydrochloride (D6474 hydrochloride) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib hydrochloride also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

HY-10260A

Vandetanib trifluoroacetate ZD6474 trifluoroacetate	VEGFR Autophagy Apoptosis	Cancer
Vandetanib trifluoroacetate (D6474 trifluoroacetate) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib trifluoroacetate also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

HY-10065R

Axitinib (Standard)	VEGFR PDGFR	Cancer
Axitinib (Standard) is the analytical standard of Axitinib. This product is intended for research and analytical applications. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 0.1, 0.2, 0.1-0.3, 1.6 nM for *VEGFR1, VEGFR2, VEGFR3* and PDGFRβ, respectively.

HY-10208S

Pazopanib-d6 GW786034-d₆	Isotope-Labeled Compounds VEGFR c-Kit PDGFR Autophagy FGFR	Cancer
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10208R

Pazopanib (Standard)	VEGFR c-Kit PDGFR Autophagy FGFR	Cancer
Pazopanib (Standard) is the analytical standard of Pazopanib. This product is intended for research and analytical applications. Pazopanib (GW786034) is a novel multi-target inhibitor of *VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms* with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10065S

Axitinib-13C,d3 AG-013736-¹³C，d₃	VEGFR PDGFR	Cancer
Axitinib- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.

HY-10260R

Vandetanib (Standard)	VEGFR Autophagy Apoptosis	Cancer
Vandetanib (Standard) is the analytical standard of Vandetanib. This product is intended for research and analytical applications. Vandetanib (D6474) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

HY-50905S

Dovitinib-d8	FLT3 c-Kit FGFR VEGFR PDGFR c-Fms	Cancer
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively[1][2].

HY-10260S1

Vandetanib-d4	Isotope-Labeled Compounds VEGFR Autophagy Apoptosis	Cancer
Vandetanib-d₄ is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].

HY-10260S

Vandetanib-d6 ZD6474-d₆	Isotope-Labeled Compounds VEGFR Autophagy Apoptosis	Cancer
Vandetanib-d₆ is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].

HY-10260S2

Vandetanib-13C6 ZD6474-¹³C₆	Isotope-Labeled Compounds VEGFR Autophagy Apoptosis	Cancer
Vandetanib-13C6 is a deuterated labeled Vandetanib . Vandetanib (D6474) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

HY-10065S1

Axitinib-d3 AG-013736-d₃	VEGFR	Cancer
Axitinib-d₃ (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively[1].

HY-119367

ODM-203	FGFR VEGFR	Cancer
ODM-203 is an orally active and selective *FGFR/VEGFR* inhibitor with IC₅₀ values of 6, 11, 16, 5, 9, 26 and 35 nM for FGFR3/1/2 and *VEGFR3/2/1/4*, respectively. ODM-203 has strong anti-tumour activity and activates immune responses in the tumour microenvironment .

HY-168114

Multi-kinase inhibitor 3	FLT3 PDGFR VEGFR	Cancer
Multi-kinase inhibitor 3 (compound 12) is a potent and orally active multikinase inhibitor with IC₅₀ values of 1.59, 1.23, 1.19, 0.59, 0.22, 1.15 nM for FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, PDGFRβ, respectively. Multi-kinase inhibitor 3 shows antiproliferative activity. Multi-kinase inhibitor 3 shows anticancer activity .

HY-10208S1

Pazopanib-13C,d3 GW786034-¹³C,d₃	VEGFR PDGFR Autophagy FGFR c-Kit	Cancer
Pazopanib- ¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib[1]. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-12009S

Pazopanib-13C,d3 hydrochloride GW786034-¹³C,d₃ hydrochloride	VEGFR PDGFR Autophagy c-Fms FGFR c-Kit	Cancer
Pazopanib- ¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-50905

Dovitinib 5+ Cited Publications CHIR-258; TKI258	FLT3 c-Kit FGFR VEGFR PDGFR c-Fms	Cancer
Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC₅₀s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, *VEGFR1/VEGFR2/VEGFR3* and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity .

HY-124526

Chiauranib Ibcasertib; CS2164	VEGFR PDGFR c-Kit Aurora Kinase c-Fms	Cancer
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, *VEGFR2, VEGFR3, PDGFRα* and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC₅₀ values ranging from 1-9 nM. Chiauranib has strongly anticancer effects .

HY-10201A

Sorafenib Tosylate Maximum Cited Publications 188 Publications Verification Bay 43-9006 Tosylate	Raf VEGFR FLT3 Autophagy Ferroptosis Apoptosis	Cancer
Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for *VEGFR2, VEGFR3, PDGFRβ, FLT3* and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator .

HY-10201

Sorafenib Maximum Cited Publications 188 Publications Verification Bay 43-9006	Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis	Cancer
Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for *VEGFR2, VEGFR3, PDGFRβ, FLT3* and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-10201AR

Sorafenib Tosylate (Standard)	Raf VEGFR FLT3 Autophagy Ferroptosis Apoptosis	Cancer
Sorafenib (Tosylate) (Standard) is the analytical standard of Sorafenib (Tosylate). This product is intended for research and analytical applications. Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for *VEGFR2, VEGFR3, PDGFRβ, FLT3* and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator .

HY-10201R

Sorafenib (Standard)	Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis	Cancer
Sorafenib (Standard) is the analytical standard of Sorafenib. This product is intended for research and analytical applications. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for *VEGFR2, VEGFR3, PDGFRβ, FLT3* and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-16961

Sitravatinib 3 Publications Verification MGCD516; MG-516	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

HY-16961A

Sitravatinib malate MGCD516 malate; MG-516 malate	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

Cat. No.	Product Name	Target	Research Area

HY-145633

Sozinibercept OPT 302; VGX-300	VEGFR	Cardiovascular Disease
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of *VEGF-C/D, which are the proangiogenic factors, inhibiting* angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .

Cat. No.	Product Name	Chemical Structure

HY-10201S

Sorafenib-d3
Sorafenib-d₃ (Donafenib), a deuterated compound of Sorafenib, is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC₅₀s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively .

HY-10208S

Pazopanib-d6
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10065S

Axitinib-13C,d3
Axitinib- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.

HY-10065S1

Axitinib-d3
Axitinib-d₃ (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively[1].

HY-10201S1

Sorafenib-d4
Sorafenib-d₄ is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively[1][2].

HY-10260S1

Vandetanib-d4
Vandetanib-d₄ is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].

HY-10260S

Vandetanib-d6
Vandetanib-d₆ is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].

HY-10260S2

Vandetanib-13C6
Vandetanib-13C6 is a deuterated labeled Vandetanib . Vandetanib (D6474) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

HY-10208S1

Pazopanib-13C,d3
Pazopanib- ¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib[1]. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-12009S

Pazopanib-13C,d3 hydrochloride
Pazopanib- ¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-10201S2

Sorafenib-13C,d3

1 Publications Verification

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: